PlGF Activators
Placental Growth Factor (PlGF) activators belong to a class of chemical compounds that are designed to interact with and modulate the activity of the PlGF protein. PlGF is a member of the vascular endothelial growth factor (VEGF) family and plays a crucial role in angiogenesis, the process by which new blood vessels are formed from existing ones. These activators are developed to influence the signaling pathways associated with PlGF, which in turn can have various effects on vascular development and remodeling.
PlGF, primarily produced in the placenta, is known to bind to its receptors on the surface of endothelial cells, thereby initiating a cascade of events leading to the formation of new blood vessels. This process is essential for various physiological processes such as embryonic development, wound healing, and tissue repair. Compounds categorized as PlGF activators are designed to either enhance or inhibit the activity of PlGF, depending on their specific mechanism of action. By modulating PlGF activity, these compounds influence the rate and extent of angiogenesis, which is relevant in diverse contexts, from pathological conditions like cancer and ischemic diseases to normal tissue development and repair.
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Cobimetinib | 934660-93-2 | sc-507421 | 5 mg | $270.00 | ||
By inhibiting MEK, it may affect pathways that indirectly regulate PlGF expression. | ||||||
Regorafenib | 755037-03-7 | sc-477163 sc-477163A | 25 mg 50 mg | $320.00 $430.00 | 3 | |
A multi-kinase inhibitor that could influence PlGF levels through its action on VEGF receptors. | ||||||
Pazopanib | 444731-52-6 | sc-396318 sc-396318A | 25 mg 50 mg | $130.00 $182.00 | 2 | |
Another VEGF receptor inhibitor, possibly affecting PlGF indirectly. | ||||||
Vandetanib | 443913-73-3 | sc-220364 sc-220364A | 5 mg 50 mg | $167.00 $1353.00 | ||
Inhibits VEGF receptors, potentially influencing PlGF levels. | ||||||
BIBF1120 | 656247-17-5 | sc-364433 sc-364433A | 5 mg 10 mg | $184.00 $321.00 | 2 | |
A tyrosine kinase inhibitor that may affect PlGF activity through VEGF receptor inhibition. | ||||||
XL-184 free base | 849217-68-1 | sc-364657 sc-364657A | 5 mg 10 mg | $94.00 $208.00 | 1 | |
Targets VEGF receptors, potentially impacting PlGF indirectly. | ||||||
Lenvatinib | 417716-92-8 | sc-488530 sc-488530A sc-488530B | 5 mg 25 mg 100 mg | $182.00 $661.00 $1690.00 | 3 | |
Inhibits multiple tyrosine kinases, including VEGF receptors, potentially affecting PlGF. | ||||||